CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.0769
6.1%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0862
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.1469
Open* 1.1769
1-Year Change* -12.05%
Day's Range* 1.0769 - 1.1769
52 wk Range 1.00-2.00
Average Volume (10 days) 24.41K
Average Volume (3 months) 891.09K
Market Cap 12.22M
P/E Ratio -100.00K
Shares Outstanding 11.75M
Revenue N/A
EPS -0.77
Dividend (Yield %) N/A
Beta 0.68
Next Earnings Date Feb 12, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 19, 2024 1.0769 -0.1000 -8.50% 1.1769 1.1769 1.0769
Apr 18, 2024 1.1469 0.0200 1.77% 1.1269 1.1569 1.1269
Apr 17, 2024 1.1269 0.0000 0.00% 1.1269 1.1769 1.1269
Apr 16, 2024 1.1069 -0.0400 -3.49% 1.1469 1.1869 1.1069
Apr 15, 2024 1.1269 -0.0800 -6.63% 1.2069 1.2369 1.0969
Apr 12, 2024 1.2069 0.0000 0.00% 1.2069 1.2469 1.2069
Apr 11, 2024 1.2469 -0.0200 -1.58% 1.2669 1.2869 1.2269
Apr 10, 2024 1.2569 -0.0100 -0.79% 1.2669 1.2969 1.2569
Apr 9, 2024 1.3169 0.0000 0.00% 1.3169 1.3669 1.2869
Apr 8, 2024 1.3269 0.0400 3.11% 1.2869 1.3469 1.2669
Apr 5, 2024 1.3269 0.0400 3.11% 1.2869 1.4269 1.2669
Apr 4, 2024 1.3069 0.1100 9.19% 1.1969 1.4469 1.1969
Apr 3, 2024 1.1769 0.0100 0.86% 1.1669 1.2569 1.1669
Apr 2, 2024 1.2269 0.0400 3.37% 1.1869 1.2469 1.1569
Apr 1, 2024 1.2969 0.2000 18.23% 1.0969 1.3269 1.0969
Mar 28, 2024 1.1469 0.0600 5.52% 1.0869 1.1469 1.0869
Mar 27, 2024 1.1069 0.0200 1.84% 1.0869 1.1269 1.0869
Mar 26, 2024 1.1069 0.0100 0.91% 1.0969 1.1069 1.0869
Mar 25, 2024 1.0969 -0.0200 -1.79% 1.1169 1.1169 1.0969
Mar 22, 2024 1.0869 0.0000 0.00% 1.0869 1.1169 1.0869

NanoViricides, Inc. Events

Time (UTC) Country Event
Monday, May 13, 2024

Time (UTC)

20:00

Country

US

Event

Q3 2024 NanoViricides Inc Earnings Release
Q3 2024 NanoViricides Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total revenue 0 0 0 0 0
Total Operating Expense 8.94347 8.1136 8.74411 7.99646 8.65968
Selling/General/Admin. Expenses, Total 2.55105 2.32874 2.62957 3.30094 2.73796
Research & Development 6.39241 5.78486 6.11454 4.69552 5.92172
Operating Income -8.94347 -8.1136 -8.74411 -7.99646 -8.65968
Interest Income (Expense), Net Non-Operating 0.35489 0.00674 -0.07606 -5.30741 0.23524
Other, Net -0.14267 0
Net Income Before Taxes -8.58857 -8.10686 -8.82219 -13.4465 -8.42444
Net Income After Taxes -8.58857 -8.10686 -8.82219 -13.4465 -8.42444
Net Income Before Extra. Items -8.58857 -8.10686 -8.82219 -13.4465 -8.42444
Net Income -8.58857 -8.10686 -8.82219 -13.4465 -8.42444
Income Available to Common Excl. Extra. Items -8.58857 -8.10686 -8.82219 -13.4465 -8.42444
Income Available to Common Incl. Extra. Items -8.58857 -8.10686 -8.82219 -13.4465 -8.42444
Diluted Net Income -8.58857 -8.10686 -8.82219 -13.4465 -8.42444
Diluted Weighted Average Shares 11.6262 11.5347 10.901 5.61673 3.59007
Diluted EPS Excluding Extraordinary Items -0.73872 -0.70282 -0.8093 -2.39402 -2.34659
Diluted Normalized EPS -0.73872 -0.70282 -0.80912 -2.39402 -2.34659
Unusual Expense (Income) 0 0
Revenue 0 0
Total Extraordinary Items
Gain (Loss) on Sale of Assets 0 -0.00203
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Revenue
Total Operating Expense 3.67637 1.81074 1.83399 1.62236 1.79278
Selling/General/Admin. Expenses, Total 0.76342 0.61465 0.66328 0.5097 0.62122
Research & Development 2.91295 1.19609 1.17071 1.11266 1.17156
Operating Income -3.67637 -1.81074 -1.83399 -1.62236 -1.79278
Interest Income (Expense), Net Non-Operating 0.10638 0.10794 0.08886 0.05172 0.01279
Gain (Loss) on Sale of Assets 0
Net Income Before Taxes -3.56999 -1.7028 -1.74513 -1.57064 -1.78
Net Income After Taxes -3.56999 -1.7028 -1.74513 -1.57064 -1.78
Net Income Before Extra. Items -3.56999 -1.7028 -1.74513 -1.57064 -1.78
Net Income -3.56999 -1.7028 -1.74513 -1.57064 -1.78
Income Available to Common Excl. Extra. Items -3.56999 -1.7028 -1.74513 -1.57064 -1.78
Income Available to Common Incl. Extra. Items -3.56999 -1.7028 -1.74513 -1.57064 -1.78
Diluted Net Income -3.56999 -1.7028 -1.74513 -1.57064 -1.78
Diluted Weighted Average Shares 11.6667 11.636 11.6103 11.5924 11.5576
Diluted EPS Excluding Extraordinary Items -0.306 -0.14634 -0.15031 -0.13549 -0.15401
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -0.306 -0.14634 -0.15031 -0.13549 -0.15401
  • Annual
  • Quarterly
2023 2022 2021 2020 2019
Total Current Assets 8.44529 14.4164 20.8238 13.9857 2.82542
Cash and Short Term Investments 8.14981 14.0664 20.5167 13.7086 2.55521
Cash & Equivalents 8.14981 14.0664 20.5167 13.7086 2.55521
Prepaid Expenses 0.29549 0.35002 0.3071 0.27706 0.27021
Total Assets 16.8999 23.4949 30.2623 23.9143 13.4485
Property/Plant/Equipment, Total - Net 8.10665 8.69419 9.0849 9.54443 10.2273
Property/Plant/Equipment, Total - Gross 14.8097 14.658 14.3337 14.1008 14.0922
Accumulated Depreciation, Total -6.70308 -5.96382 -5.24877 -4.55638 -3.86493
Intangibles, Net 0.33358 0.34185 0.35012 0.35839 0.36666
Other Long Term Assets, Total 0.01436 0.04244 0.00352 0.02586 0.02919
Total Current Liabilities 0.53425 0.41284 0.35115 2.15638 2.84815
Accounts Payable 0.39049 0.27236 0.23156 0.94231 1.13368
Accrued Expenses 0.14376 0.04569 0.02429 0.06924 0.06887
Notes Payable/Short Term Debt 0 0.09479 0.09531 1.14483 0
Other Current Liabilities, Total 0 1.64561
Total Liabilities 2.03425 0.41284 0.35115 2.15638 2.84815
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 1.5
Total Equity 14.8656 23.082 29.9112 21.758 10.6004
Preferred Stock - Non Redeemable, Net 0.00001 0.00049 0.00037 0.00037 0.00511
Common Stock 0.00012 0.01159 0.01152 0.00908 0.0769
Additional Paid-In Capital 145.946 145.562 144.285 127.312 102.635
Retained Earnings (Accumulated Deficit) -131.081 -122.492 -114.385 -105.563 -92.1166
Total Liabilities & Shareholders’ Equity 16.8999 23.4949 30.2623 23.9143 13.4485
Total Common Shares Outstanding 11.6985 11.5922 11.5152 9.08341 3.84491
Total Preferred Shares Outstanding 0.54767 0.48458 0.37149 0.3686 5.11404
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 7.14311 8.44529 9.93108 11.5529 13.1496
Cash and Short Term Investments 6.96982 8.14981 9.65096 11.4483 12.918
Cash & Equivalents 6.96982 8.14981 9.65096 11.4483 12.918
Prepaid Expenses 0.17328 0.29549 0.28012 0.10455 0.23156
Total Assets 15.4168 16.8999 18.5768 20.335 22.0823
Property/Plant/Equipment, Total - Net 7.92788 8.10665 8.2909 8.41785 8.55737
Property/Plant/Equipment, Total - Gross 14.818 14.8097 14.8072 14.7479 14.7025
Accumulated Depreciation, Total -6.89014 -6.70308 -6.51627 -6.33001 -6.14516
Intangibles, Net 0.33151 0.33358 0.33565 0.33771 0.33978
Other Long Term Assets, Total 0.01432 0.01436 0.01918 0.02651 0.03559
Total Current Liabilities 0.94831 0.53425 0.34874 0.46459 0.51836
Accounts Payable 0.60869 0.39049 0.30658 0.41272 0.47081
Accrued Expenses 0.33962 0.14376 0.04217 0.05188 0.02371
Notes Payable/Short Term Debt 0 0 0 0 0.02384
Total Liabilities 2.44831 2.03425 0.34874 0.46459 0.51836
Total Long Term Debt 0 0 0 0 0
Total Equity 12.9685 14.8656 18.2281 19.8704 21.564
Preferred Stock - Non Redeemable, Net 0.00001 0.00001 0.0005 0.0005 0.0005
Common Stock 0.00012 0.00012 0.01167 0.01163 0.01161
Additional Paid-In Capital 146.018 145.946 145.727 145.666 145.615
Retained Earnings (Accumulated Deficit) -133.049 -131.081 -127.511 -125.808 -124.063
Total Liabilities & Shareholders’ Equity 15.4168 16.8999 18.5768 20.335 22.0823
Total Common Shares Outstanding 11.7456 11.6985 11.6665 11.6346 11.61
Total Preferred Shares Outstanding 0.55827 0.54767 0.49729 0.49556 0.49517
Other Current Assets, Total
Other Liabilities, Total 1.5 1.5
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -8.10686 -8.82219 -13.4465 -8.42444 -8.56346
Cash From Operating Activities -5.89125 -8.21384 -6.6656 -6.80277 -7.77587
Cash From Operating Activities 0.71506 0.69627 0.69145 0.68764 0.67179
Amortization 0.00827 0.00827 0.00827 0.00827 0.00827
Non-Cash Items 1.27772 0.44393 5.96155 0.35805 0.07515
Cash Taxes Paid 0 0 0 0
Cash Interest Paid 0.00512 0.00486 0 0 0.16667
Changes in Working Capital 0.21456 -0.54011 0.11966 0.56771 0.03238
Cash From Investing Activities -0.32435 -0.23876 -0.00864 -0.07379 -0.24182
Capital Expenditures -0.32435 -0.23876 -0.00864 -0.07379 -0.24182
Other Investing Cash Flow Items, Total
Cash From Financing Activities -0.23472 15.2607 17.8276 2.35 0
Issuance (Retirement) of Stock, Net 0 16.5637 16.677 2.35
Issuance (Retirement) of Debt, Net -0.23472 -1.30301 1.16284 0 0
Net Change in Cash -6.45032 6.80808 11.1534 -4.52656 -8.01769
Financing Cash Flow Items -0.01219
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -5.01858 -3.31578 -1.57064 -8.10686 -6.32687
Cash From Operating Activities -4.17147 -2.43338 -1.03286 -5.89125 -4.49355
Cash From Operating Activities 0.55245 0.36619 0.18134 0.71506 0.52917
Amortization 0.0062 0.00414 0.00207 0.00827 0.0062
Non-Cash Items 0.16461 0.10412 0.05259 1.27772 1.17355
Cash Interest Paid 0.00094 0.00094 0.00084 0.00512 0.00349
Changes in Working Capital 0.12386 0.40795 0.30179 0.21456 0.1244
Cash From Investing Activities -0.14915 -0.08985 -0.04451 -0.32435 -0.24899
Capital Expenditures -0.14915 -0.08985 -0.04451 -0.32435 -0.24899
Cash From Financing Activities -0.09479 -0.09479 -0.07095 -0.23472 -0.20201
Issuance (Retirement) of Stock, Net 0 0
Issuance (Retirement) of Debt, Net -0.09479 -0.09479 -0.07095 -0.23472 -0.1646
Net Change in Cash -4.4154 -2.61801 -1.14832 -6.45032 -4.94454
Cash Taxes Paid 0
Financing Cash Flow Items 0 -0.03741

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

NanoViricides, Inc. Company profile

About NanoViricides Inc

NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is engaged in discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. The nanomedicines technology also enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company is developing antiviral drug candidate, NV-CoV-2 drug for the treatment of COVID-19 infected sick persons. Its other clinical drug candidate NV-HHV-101 a skin cream for the treatment of shingles rash.

Financial summary

BRIEF: For the six months ended 31 December 2021, NanoViricides Inc revenues was not reported. Net loss decreased 2% to $4.5M. Lower net loss reflects General and administrative decrease of 21% to $1.2M (expense), Interest expense decrease of 96% to $4K (expense), Loss on disposal of property and equip. decrease from $2K (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.44 to -$0.39.

Equity composition

Common Stock $.001 Par, 2/11, 300M auth., 139,906,601 issd. Insider owns 30.00%. Conv. Pref. Stock Class A $.001 Par, 10M auth., 7,593,750 issd. 09/13, 1-for-3.5 Reverse Stock split.

Industry: Bio Therapeutic Drugs

1 Controls Drive
SHELTON
CONNECTICUT 06484
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

ETH/USD

3,174.86 Price
+3.490% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

17,037.80 Price
-1.980% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

BTC/USD

65,297.15 Price
+2.030% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.53 Price
+4.830% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading